Significant efficacy of conversion therapy for advanced hepatocellular carcinoma: a case report

Abstract

Abstract Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related mortality worldwide [1]. This study aimed to report a case with advanced-stage HCC who underwent transhepatic arterial chemotherapy and embolization combined with anlotinib, sintilimab, and radiotherapy. He successfully received conversion therapy to get tumor downstaging and finally had an opportunity to undergo a right lobe hepatectomy. The postoperative pathological examination confirmed a pathologic complete response, and the level of serum alpha-fetoprotein decreased from > 1000 to 11.33 ng/mL. The follow-up to date revealed that the progression-free survival time was more than 13 months. It indicated that combined therapy might be a superior choice for the conversion therapy of patients with advanced-stage HCC.